Randomized phase II trial of capecitabine (X) versus X plus erlotinib (E) in patients (pts) with metastatic colorectal cancer (mCRC)

Trial Profile

Randomized phase II trial of capecitabine (X) versus X plus erlotinib (E) in patients (pts) with metastatic colorectal cancer (mCRC)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2011

At a glance

  • Drugs Erlotinib (Primary) ; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2011 The erlotinib arm was discontinued due to lack of efficacy after a preplanned interim analysis.
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 09 Mar 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top